Company profile
Stoke Therapeutics, Inc.
NASDAQ:STOKBiotechnology: Pharmaceutical Preparations
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| Zorevunersen | phase3 | — | 2 | active |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (3)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT06872125 | phase3 | recruiting | 2025-06-04 | 2027-03-01 | Stoke Therapeutics, Inc | A Double-blind Study Evaluating the Efficacy, Safety, and Tolerability of Zorevunersen in Patients With Dravet Syndrome |
| NCT04740476 | phase2 | active_not_recruiting | 2021-01-20 | 2029-03-31 | Stoke Therapeutics, Inc | An Open-Label Extension Study of STK-001 for Patients With Dravet Syndrome |
| NCT04442295 | phase1_2 | completed | 2020-06-29 | 2023-11-14 | Stoke Therapeutics, Inc | An Open-Label Study to Investigate the Safety of Single and Multiple Ascending Doses in Children and Adolescents With Dravet Syndrome |
FDA applications (0)
No records yet.